...$275.3 Specialty pharma: cardiovascular and metabolic disorders Other M&A Target Acquirer Acq value Raised Focus AdProTech Ltd....

...Positions will be cut across the combined operations of the company and its recent acquisition, Adprotech Ltd....

...IZP completed its previously announced acquisition of Adprotech for 12.7 million shares, valued at C$18.4 million...
...C$1.45 on April 20. The deal was announced earlier this month (see BioCentury, April 12). Adprotech Ltd....

...technology platform in complement inhibition, and Adprotech's Prodaptin drug targeting system. The deal also includes Adprotech's...
...solid organ transplantation. On closing, Adprotech shareholders will hold about 12% of IZP's outstanding shares. Adprotech...
...licensed to Adprotech certain components of its IP that cover complement inhibition. The license enables Adprotech...

...Inflazyme (TSE:IZP) said it will acquire Adprotech (Cambridge, U.K.) in a stock deal worth about C$20...
...inflammation technology platform in complement inhibition, and Adprotech's Prodaptin drug-targeting system. The deal also includes Adprotech's...
...the merged company. Upon closing, Adprotech shareholders will hold about 12% of IZP's outstanding shares. Adprotech...

...diagnostic products Company Status Country Active Biotech (CSE:ACTIB) Ph II Sweden Addex Ph II Switzerland AdProTech...

...The FDA granted Orphan Drug designation to Adprotech's APT070 to prevent delayed graft function in solid...
...2002. The compound is in Phase II testing for the indication and for rheumatoid arthritis. Adprotech Ltd....

...104838 Anti-TNF antisense inhibitor Ph II Elan Roche MRA IL-6 receptor antagonist Ph II Chugai Adprotech...

...Gyros $29.3 De Novo $28.3 Affibody $28.0 Lorantis $27.9 Munich $27.8 Paion $27.3 Graffinity $27.2 AdProTech...

...study in 45 transplant patients. APT070 also is in Phase II testing for rheumatoid arthritis. Adprotech Ltd....